scholarly article | Q13442814 |
P50 | author | Eric J Small | Q97531370 |
Michael A. Carducci | Q114718060 | ||
Michael J. Morris | Q38329744 | ||
Philip W. Kantoff | Q42532150 | ||
Susan Halabi | Q42896002 | ||
P2093 | author name string | Daniel George | |
Nicholas J Vogelzang | |||
Walter M Stadler | |||
J Paul Monk | |||
William Kevin Kelly | |||
John F Mahoney | |||
Ellen Kaplan | |||
P2860 | cites work | Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study | Q46817220 |
Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer | Q53308080 | ||
Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer | Q60156367 | ||
Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen | Q79314357 | ||
Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study | Q84792458 | ||
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer | Q33561160 | ||
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. | Q33767866 | ||
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 | Q33813718 | ||
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer | Q34281216 | ||
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. | Q34441553 | ||
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline | Q34523108 | ||
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Q34586436 | ||
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma | Q35833169 | ||
Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells | Q38474642 | ||
Expression of vascular endothelial growth factor receptors in human prostate cancer | Q42477154 | ||
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study | Q43566256 | ||
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. | Q44381567 | ||
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. | Q46365760 | ||
P433 | issue | 13 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | prostate cancer | Q181257 |
bevacizumab | Q413299 | ||
docetaxel | Q420436 | ||
placebo | Q269829 | ||
phase III clinical trial | Q42824827 | ||
P304 | page(s) | 1534-1540 | |
P577 | publication date | 2012-03-26 | |
P1433 | published in | Journal of Clinical Oncology | Q400292 |
P1476 | title | Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401 | |
P478 | volume | 30 |
Q39863679 | A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy |
Q47564776 | A Simple Method for Deriving the Confidence Regions for the Penalized Cox's Model via the Minimand Perturbation |
Q95261850 | A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy |
Q36934749 | A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases |
Q92379255 | A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China |
Q33439003 | A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study |
Q35018896 | A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer |
Q40120703 | A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. |
Q40182500 | A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer |
Q34657338 | A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer |
Q36984477 | A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma |
Q54364572 | A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer. |
Q33415009 | A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients |
Q46867730 | A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer |
Q88186567 | A recipe for targeted therapy in prostate cancer |
Q45094027 | Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of (131)I-L19SIP in a prostate cancer patient |
Q35999102 | Acute Respiratory Distress Syndrome after Treatment of Metastatic Prostate Cancer with Taxotere: A Case Report and Literature Review |
Q53561315 | Addressing apoptosis to tumor zip codes. |
Q38890711 | Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. |
Q38282461 | Advances in systemic therapies for metastatic castration-resistant prostate cancer |
Q44187537 | Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. |
Q31152878 | An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients |
Q26799813 | Androgen deprivation of prostate cancer: Leading to a therapeutic dead end |
Q44114886 | Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. |
Q57139434 | Angiogenesis inhibitors in the treatment of prostate cancer |
Q42332732 | Another disappointing result, but how good is it? |
Q36936900 | Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? |
Q36330281 | Anti-VEGF therapies in the clinic |
Q26851183 | Anti-angiogenesis in prostate cancer: knocked down but not out |
Q33770680 | Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions |
Q47147286 | Antiangiogenic therapies in urogenital malignancies: Fiction or fact? |
Q36563542 | Antiangiogenic therapy for cancer: an update |
Q53664329 | Antiangiogenic therapy--evolving view based on clinical trial results. |
Q35966757 | Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. |
Q39000185 | Antibody therapeutics for treating prostate cancer: where are we now and what comes next? |
Q38099046 | Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer |
Q87115788 | Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy |
Q35202464 | Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). |
Q87060049 | Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis |
Q43497234 | Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups |
Q38237318 | Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups |
Q41612851 | Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis |
Q38024852 | Bevacizumab treatment of prostate cancer |
Q57456564 | Biomarkers and Bone Imaging Dynamics associated with Clinical outcomes of Oral Cabozantinib Therapy in Metastatic Castrate Resistant Prostate Cancer |
Q34695003 | Biomarkers for anti-angiogenic therapy in cancer. |
Q36243296 | Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer |
Q38136271 | Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer |
Q33864723 | Bone-targeting agents in prostate cancer |
Q38066590 | Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario. |
Q33946929 | Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial |
Q57107233 | Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer? |
Q38371293 | Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients |
Q39002111 | Cardiovascular toxicities of systemic treatments of prostate cancer. |
Q38076273 | Castrate-resistant prostate cancer: postdocetaxel management |
Q35864027 | Castration-resistant prostate cancer: mechanisms, targets, and treatment. |
Q35865011 | Castration-resistant prostate cancer: systemic therapy in 2012 |
Q39511732 | Castration-resistant prostate cancer: targeted therapies and individualized treatment |
Q38121792 | Cell mates: paracrine and stromal targets for prostate cancer therapy. |
Q36181578 | Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures |
Q35776240 | Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer |
Q27008883 | Chemotherapy and its evolving role in the management of advanced prostate cancer |
Q38555599 | Chemotherapy in Prostate Cancer |
Q28078477 | Chemotherapy options in castration-resistant prostate cancer |
Q27334654 | Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial |
Q99629837 | Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review |
Q39247534 | Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models |
Q58579384 | Combined Performance of Screening and Variable Selection Methods in Ultra-High Dimensional Data in Predicting Time-To-Event Outcomes |
Q94528678 | Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel |
Q39427133 | Comparison of futility monitoring guidelines using completed phase III oncology trials |
Q34386577 | Critical appraisal of cabazitaxel in the management of advanced prostate cancer |
Q38030595 | Current and emerging treatments in the management of castration-resistant prostate cancer |
Q36253388 | Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer |
Q38317384 | Current role of cabozantinib in metastatic castration-resistant prostate cancer |
Q37860950 | Current treatment strategies for castration-resistant prostate cancer |
Q51102220 | Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. |
Q91996335 | Developing and Validating Risk Assessment Models of Clinical Outcomes in Modern Oncology |
Q38208820 | Development of cabozantinib for the treatment of prostate cancer |
Q42183155 | Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: A case report |
Q28294857 | Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial |
Q41082307 | Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial |
Q35572535 | Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial |
Q41704777 | Docetaxel for advanced prostate cancer: how early to start? |
Q44701341 | Docetaxel in castration-resistant prostate cancer: a single-centre experience. |
Q33416977 | Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. |
Q42125455 | Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer |
Q35298058 | Docetaxel-based therapy with and without antiangiogenic agents as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of nine randomized controlled trials |
Q38028012 | Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer |
Q38815759 | Dose-Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin-Coated PGMA Nanoparticles. |
Q50850244 | Drug development in prostate cancer: time to embrace RECIST? |
Q34139362 | Drug resistance in metastatic castration-resistant prostate cancer |
Q30538388 | Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy |
Q37721529 | Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls |
Q35764986 | Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis |
Q42970939 | ECF chemotherapy for liver metastases due to castration-resistant prostate cancer |
Q57107045 | Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials |
Q26786618 | Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
Q46024539 | Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review. |
Q52592629 | Emerging Therapies in Metastatic Prostate Cancer. |
Q38586459 | Emerging agents for the therapy of advanced prostate cancer |
Q38166018 | Emerging drugs for prostate cancer. |
Q37980450 | Emerging novel therapies for advanced prostate cancer |
Q35999255 | Emerging targeted therapies for castration-resistant prostate cancer |
Q37876194 | Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer |
Q34367585 | End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review |
Q37425136 | Enhanced diagnostic accuracy for quantitative bone scan using an artificial neural network system: a Japanese multi-center database project |
Q36353291 | Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer |
Q27010542 | Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer |
Q26861575 | Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223 |
Q37311904 | Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis. |
Q36293995 | From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer |
Q37826274 | Future directions in castrate-resistant prostate cancer therapy. |
Q33621387 | Glucocorticoids and prostate cancer treatment: friend or foe? |
Q26827975 | Growth factor and signaling pathways and their relevance to prostate cancer therapeutics |
Q64124364 | Identification of a Genomic Region between and Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance) |
Q43867243 | Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment. |
Q38959645 | Immunotherapy for prostate cancer: False promises or true hope? |
Q50420907 | Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer |
Q39349569 | Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer |
Q38956775 | Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. |
Q38480926 | In vivo passage of human prostate cancer cells in mice results in stable gene expression changes affecting numerous cancer-associated biological processes |
Q36729895 | Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials |
Q33904867 | Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis |
Q38261859 | Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials |
Q35745925 | KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells |
Q38050465 | Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer |
Q39204706 | Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer. |
Q47122203 | Liver Metastases in Prostate Carcinoma Represent a Relatively Aggressive Subtype Refractory to Hormonal Therapy and Short-Duration Response to Docetaxel Monotherapy |
Q34608976 | Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer |
Q37388624 | Low dose of interferon-α improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study |
Q40645773 | Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit? |
Q35575488 | MET and VEGF: synergistic targets in castration-resistant prostate cancer |
Q37354571 | Management of docetaxel failures in metastatic castrate-resistant prostate cancer |
Q26851177 | Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant |
Q35948297 | Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer |
Q38181005 | Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics |
Q26799585 | Molecular landscape of prostate cancer: implications for current clinical trials |
Q30393012 | Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer |
Q37127044 | Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer |
Q35955451 | Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer |
Q36866291 | New and emerging therapies for bone metastases in genitourinary cancers |
Q38206684 | New developments in the treatment of castration resistant prostate cancer |
Q42344607 | New immunotherapeutic paradigms for castration-resistant prostate cancer |
Q91045442 | Non-proteolytic calpain-6 interacts with VEGFA and promotes angiogenesis by increasing VEGF secretion |
Q38116358 | Novel therapeutic approaches for the treatment of castration-resistant prostate cancer |
Q34249263 | Novel therapies for metastatic castrate-resistant prostate cancer |
Q36665708 | Novel therapies for the treatment of advanced prostate cancer |
Q37227787 | On model specification and selection of the Cox proportional hazards model. |
Q89682703 | Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy |
Q53266501 | Optimal management of bone metastases in prostate cancer. |
Q90699186 | Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel |
Q44640343 | Overcoming chemotherapy resistance in prostate cancer |
Q36687323 | P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer |
Q38246587 | PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials |
Q26772883 | Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science |
Q36213475 | Personalized cancer medicine--advances and socio-economic challenges |
Q36871685 | Perspectives on treatment of metastatic castration-resistant prostate cancer |
Q39796533 | Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy |
Q38267175 | Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents |
Q35328550 | Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer |
Q37218730 | Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial |
Q53702293 | Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. |
Q58596102 | Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer |
Q37137426 | Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer |
Q36864032 | Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer |
Q56334475 | Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) |
Q33406047 | Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer |
Q33429309 | Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. |
Q92451337 | Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer |
Q42927772 | Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. |
Q36056197 | Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer |
Q36975969 | Potential use of custirsen to treat prostate cancer |
Q36668489 | Power and sample size calculations for SNP association studies with censored time-to-event outcomes |
Q37354526 | Preoperative therapy for localized prostate cancer: a comprehensive overview |
Q37325001 | Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy |
Q90344454 | Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways |
Q27011642 | Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies |
Q38977239 | RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. |
Q39257661 | Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer |
Q35660931 | Recent advances in the therapy of castration-resistant prostate cancer: the price of progress |
Q55343985 | Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer. |
Q38125501 | Recent advances revolutionize treatment of metastatic prostate cancer |
Q27022567 | Recent progress in pharmaceutical therapies for castration-resistant prostate cancer |
Q58729601 | Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials |
Q48272997 | Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer. |
Q33949406 | Risks and benefits with bevacizumab: evidence and clinical implications |
Q28075965 | Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer |
Q41858027 | SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing |
Q38615715 | Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). |
Q27022715 | Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy |
Q28251240 | Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer |
Q60156253 | Sipuleucel-T |
Q47772214 | Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions |
Q35128716 | Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments |
Q36285594 | Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer |
Q47234339 | Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus |
Q38974777 | Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy |
Q35555303 | Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial |
Q53772302 | Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). |
Q26852544 | Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline |
Q38295983 | Targeted prodrug approaches for hormone refractory prostate cancer. |
Q42905122 | Targeted therapy of urological tumours. Experimental field or established therapeutic approach? |
Q92446657 | Targeting Angiogenesis in Prostate Cancer |
Q36931715 | Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer |
Q41143231 | Targeting MRP4 expression by anti-androgen treatment reverses MRP4-mediated docetaxel resistance in castration-resistant prostate cancer |
Q38723404 | Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'? |
Q38053680 | Targeting angiogenesis as a promising modality for the treatment of prostate cancer |
Q37993137 | Targeting angiogenesis for the treatment of prostate cancer |
Q38184622 | Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches. |
Q88186561 | Targeting notch in prostate cancer--combination is the key |
Q27022821 | Targeting the adaptive molecular landscape of castration-resistant prostate cancer |
Q26770428 | Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects |
Q38075446 | Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer. |
Q39231548 | The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer |
Q38938475 | The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease |
Q36163344 | The STAMPEDE trial: paradigm-changing data through innovative trial design |
Q35039889 | The biology of castration-resistant prostate cancer |
Q36515526 | The changing landscape in the treatment of metastatic castration-resistant prostate cancer |
Q37913983 | The changing therapeutic landscape of castration-resistant prostate cancer |
Q35059214 | The course of metastatic prostate cancer under treatment |
Q41830553 | The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer. |
Q37227713 | The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90 |
Q38769470 | The evolving role of chemotherapy in prostate cancer |
Q38374417 | The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer |
Q90663624 | The future of clinical trials in urological oncology |
Q46720614 | The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy |
Q26824086 | The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review |
Q28687241 | The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer |
Q42575268 | The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions |
Q38575004 | The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target |
Q38223389 | The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer |
Q36326737 | Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer |
Q38195723 | Therapeutic options and multifaceted treatment paradigms in metastatic castrate-resistant prostate cancer |
Q47121370 | Toxicity, Adverse Events, and Quality of Life Associated with the Treatment of Metastatic Castration-Resistant Prostate Cancer |
Q49578235 | Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer |
Q56932681 | Trial watch: Monoclonal antibodies in cancer therapy |
Q28550733 | Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy |
Q45719740 | Tumour angiogenesis: an elusive target in castration-resistant prostate cancer |
Q38262816 | Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development |
Q38176143 | Update in systemic therapy of urologic malignancies. |
Q37590738 | Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. |
Q87197964 | Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs? |
Q38086420 | Validation and clinical utility of prostate cancer biomarkers. |
Q38745926 | Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. |
Q91997710 | Vessel co-option in cancer |
Q57133648 | [Therapy of castration-resistant prostate cancer] |
Search more.